πŸ‡ΊπŸ‡Έ FDA
Patent

US 11530411

Methods for reducing LRRK2 expression

granted A61KA61K31/7115A61K31/712

Quick answer

US patent 11530411 (Methods for reducing LRRK2 expression) held by Ionis Pharmaceuticals, Inc. expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K31/7115, A61K31/712, A61K31/7125, A61P